You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR KYMRIAH


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for KYMRIAH

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02529813 ↗ CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Active, not recruiting Intrexon Corporation Phase 1 2015-12-16 This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia.
NCT02529813 ↗ CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Active, not recruiting National Cancer Institute (NCI) Phase 1 2015-12-16 This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia.
NCT02529813 ↗ CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Active, not recruiting Ziopharm Phase 1 2015-12-16 This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia.
NCT02529813 ↗ CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Active, not recruiting Ziopharm Oncology Phase 1 2015-12-16 This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia.
NCT02529813 ↗ CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Active, not recruiting M.D. Anderson Cancer Center Phase 1 2015-12-16 This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia.
NCT03628053 ↗ Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Withdrawn Novartis Pharmaceuticals Phase 3 2020-06-05 This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for KYMRIAH

Condition Name

Condition Name for KYMRIAH
Intervention Trials
Recurrent Diffuse Large B-Cell Lymphoma 3
Refractory Diffuse Large B-Cell Lymphoma 3
Acute Lymphoblastic Leukemia 3
B Acute Lymphoblastic Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for KYMRIAH
Intervention Trials
Lymphoma 6
Lymphoma, B-Cell 6
Lymphoma, Large B-Cell, Diffuse 4
Leukemia, Lymphoid 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for KYMRIAH

Trials by Country

Trials by Country for KYMRIAH
Location Trials
United States 7
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for KYMRIAH
Location Trials
Minnesota 2
Missouri 1
California 1
Illinois 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for KYMRIAH

Clinical Trial Phase

Clinical Trial Phase for KYMRIAH
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1/Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for KYMRIAH
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 3
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for KYMRIAH

Sponsor Name

Sponsor Name for KYMRIAH
Sponsor Trials
National Cancer Institute (NCI) 3
Masonic Cancer Center, University of Minnesota 2
Novartis 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for KYMRIAH
Sponsor Trials
Other 9
Industry 7
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.